Ralph Bennett, MD
Rheumatology · Mesa, AZNPI 1366433161
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.9%), food and beverage and education — rather than concentrated in one kind of arrangement. Amgen accounts for 68.5% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $19,315 and has fallen 99.7% since, to $55 in 2025.
Across 780 payments — averaging $37.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- AbbVie$3K
- Pfizer$1K
- UCB, Inc.$772
- Novartis$653
- Johnson & Johnson$488
- plus $3K from 26 others
Across 435 payments — averaging $2835.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$370K
- UCB SA$244K
- Amgen$225K
- Janssen Research & Development, LLC$148K
- AbbVie$147K
- Astrazeneca UK Limited$43K
- plus $56K from 3 others
What the payments were for
- Consulting fees$15,45053%
- Food & beverage$13,76447%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 241 | $20,009 |
| AbbVie | 134 | $2,550 |
| Pfizer | 102 | $1,424 |
| UCB, Inc. | 43 | $772 |
| Novartis | 34 | $653 |
| Johnson & Johnson(2 entities) | 34 | $488 |
| Lilly USA, LLC | 26 | $451 |
| Genentech USA, Inc. | 32 | $436 |
| E.r. Squibb & Sons, L.L.C. | 27 | $436 |
| GSK | 26 | $388 |
| AstraZeneca(2 entities) | 10 | $268 |
| Sanofi | 13 | $258 |
| Mallinckrodt Hospital Products Inc. | 6 | $151 |
| Organon | 9 | $129 |
| Radius Health, Inc. | 5 | $105 |
| Pacira Therapeutics, Inc. | 5 | $83 |
| Bristol Myers Squibb | 5 | $83 |
| Aurinia Pharma U.S., Inc. | 5 | $81 |
| Boehringer Ingelheim | 3 | $77 |
| Mallinckrodt Enterprises LLC | 3 | $75 |
| Hikma Pharmaceuticals USA | 5 | $65 |
| Merck | 2 | $30 |
| Fidia Pharma USA Inc. | 1 | $29 |
| Bioventus LLC | 1 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $25 |
| Gilead | 1 | $23 |
| Abbott | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| Sobi, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,215 in reported general payments places this provider in the 85th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 33 | $276,298 |
| Enbrel SureclickEtanercept | 33 | $272,868 |
| EnbrelEtanercept | 22 | $177,965 |
| Enbrel MiniEtanercept | 19 | $139,635 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $99,932 |
| RinvoqUpadacitinib | 13 | $83,932 |
| Hydroxychloroquine Sulfate | 332 | $16,223 |
| MethotrexateMethotrexate Sodium | 292 | $8,012 |
| Leflunomide | 61 | $4,889 |
| Prednisone | 310 | $2,936 |
| Gabapentin | 118 | $2,718 |
| Duloxetine Hcl | 101 | $2,469 |
| Celecoxib | 39 | $1,975 |
| Azathioprine | 15 | $1,386 |
| Alendronate Sodium | 137 | $1,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $20,009 | $177,96522 claims |
| UCB, Inc.Cimzia (2 Pack) | $772 | $99,93212 claims |
| AbbVieRinvoq | $2,550 | $83,93213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 rheumatology providers in Arizona.
Other rheumatology in Mesa
- Areena SwarupMesa$29K
- Debra MichelMesa$4K
- Santina Carminati TaddeiMesa$2K
- Nehad SolomanPhoenix$1.3M
- John TesserPhoenix$999K
- Joy SchechtmanPeoria$860K
- Mona AminGlendale$446K
- Brittany PanicoGilbert$374K
- Amer Al-KhoudariChandler$369K
- Andrew SharobeemGlendale$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.